Nov. 20, 2012
/PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, announces that a class action has been filed on behalf of purchasers of the securities of Abiomed Inc. ("Abiomed" or the "Company") (NasdaqGS: ABMD), who purchased shared during the period between
August 5, 2011
October 31, 2012
, inclusive, (the "Class Period"), concerning whether the company and certain of its officers and directors have violated federal securities laws.
November 1, 2102
, shares of Abiomed plummeted 31% or
per share to close at
after the company disclosed it has been subpoenaed by the U.S. Attorney's Office for the
District of Columbia
related to an investigation into the labeling and marketing of its Impella 2.5 heart pump. The company said in a press release:
October 26, 2012
, we were informed that
the United States
Attorney's Office for the District of Columbia is conducting an investigation that is focused on the Company's marketing and labeling of the Impella 2.5. On October, 31, 2012, we accepted service of a Health Insurance Portability and Accountability Act administrative subpoena related to this investigation. The subpoena seeks documents related to the Impella 2.5 and we understand the investigation focuses primarily on marketing and labeling issues.
No Class has yet been certified in the above action. If you wish to review a copy of the Complaint, to discuss this action, or have any questions, please contact either
of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email
. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
January 15, 2013
, is the deadline for investors to seek a lead plaintiff appointment.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.